Kathryn Deacon
Family · Mayflower, ARNPI 1598289746
Payments from drug & device makers
Across 208 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$741
- AbbVie$638
- Pfizer$561
- GSK$259
- Amgen$172
- Lilly USA, LLC$152
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,902100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,902 in reported general payments places this provider in the 90th percentile of 2,103 family providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $60,681 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $51,457 |
| EliquisApixaban | 53 | $41,868 |
| FarxigaDapagliflozin Propanediol | 43 | $36,259 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $36,085 |
| JardianceEmpagliflozin | 32 | $26,589 |
| VraylarCariprazine Hcl | 17 | $26,164 |
| MounjaroTirzepatide | 21 | $24,168 |
| JanuviaSitagliptin Phosphate | 24 | $21,217 |
| GemtesaVibegron | 31 | $19,419 |
| LinzessLinaclotide | 25 | $16,704 |
| TrulicityDulaglutide | 11 | $10,246 |
| Spiriva RespimatTiotropium Bromide | 18 | $9,298 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $9,255 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $741 | $78,421108 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $259 | $62,69499 claims |
| Novo NordiskOzempic | $99 | $60,68160 claims |
| AbbVieVraylar, Linzess | $638 | $42,86842 claims |
| PfizerEliquis | $561 | $41,86853 claims |
| Lilly USA, LLCMounjaro, Trulicity | $152 | $34,41432 claims |
| MerckJanuvia | $13 | $21,21724 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $107 | $19,41931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,103 family providers in Arkansas.
Other family in Mayflower
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.